Tango Therapeutics reports 82% response rate and 88% 9‑month PFS in pancreatic cancer combo trial
Tango Therapeutics announced that its investigational PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ daraxonrasib produced an objective response rate of 82% in 22 efficacy‑evaluable pancreatic cancer patients. Nine months after treatment start, 88% of those patients remained progression‑free. The company said it will begin a global, randomized registrational Phase 3 study of the combination in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027.
Why it matters
The data triggered a sharp sell‑off in Tango’s shares, which fell between 6% and 16% in trading after the release. The decline reflects investor profit‑taking and concerns about the time horizon before a potential approval.
Key facts
- 1Objective response rate was 82% among 22 efficacy‑evaluable pancreatic cancer patients. stocktitan.net
- 2Nine‑month progression‑free survival rate was 88% in the same cohort. stocktitan.net
- 3Median follow‑up for the evaluable patients was 7.1 months. stocktitan.net
- 4Tango plans to start a global, randomized registrational Phase 3 trial of vopimetostat plus daraxonrasib in front‑line MTAP‑deleted pancreatic cancer in the first half of 2027. stocktitan.net
- 5Shares fell 6% after the data release. investing.com
- 6Pre‑market price was down 8.88% following the announcement. rttnews.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.